SCHEMBL4815513

SCHEMBL4815513

CCN(CC)CC.NC(Cc1cc(Br)c(OCc2ccccc2Cl)c(Br)c1)C(=O)O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC1A5 Q15758 1/20 0.49
PDCD1 Q15116 1/20 0.48
CD274 Q9NZQ7 1/20 0.48
THRA P10827 2/20 0.45
THRB P10828 2/20 0.45
CYP2C19 P33261 3/20 0.45
CYP1A2 P05177 2/20 0.45
CYP3A4 P08684 2/20 0.45
CYP2D6 P10635 2/20 0.45
CYP2C9 P11712 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
SLC7A5 Q01650 1/20 0.44
PPARG P37231 1/20 0.43
FABP4 P15090 3/20 0.43
FABP5 Q01469 3/20 0.43
PTPN1 P18031 1/20 0.42
MAOB P27338 2/20 0.41
MEN1 O00255 1/20 0.41
ALOX15 P16050 1/20 0.41
KMT2A Q03164 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4808835 0.83 THRA (0.56) SLC1A5THRATHRBCYP2C19CYP1A2
SCHEMBL4816034 0.83 THRB (0.47) PDCD1CD274THRATHRBCYP1A2
SCHEMBL4812514 0.82 SLC1A5 (0.47) SLC1A5PDCD1CD274THRATHRB
SCHEMBL4809557 0.81 THRA (0.45) PDCD1CD274THRATHRBSMN1; SMN2
SCHEMBL4810919 0.80 THRA (0.50) PDCD1CD274THRATHRBPPARG
SCHEMBL4809787 0.80 PTPN1 (0.64) SLC1A5PDCD1CD274THRATHRB
SCHEMBL4809817 0.80 THRB (0.46) PDCD1CD274THRATHRBCYP1A2
SCHEMBL4818644 0.78 THRA (0.48) SLC1A5PDCD1CD274THRATHRB
SCHEMBL4808246 0.77 THRA (0.46) SLC1A5THRATHRBSLC7A5PPARG
SCHEMBL6553089 0.75 THRB (0.46) PDCD1CD274THRATHRBCYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7319096-B2 Thyroid hormone receptor antagonists for cardiac and metabolic disorders II KARO BIO AB (SE) 2008-01-15 US claimed
US-20040220147-A1 Thyroid hormone receptor antagonists for cardiac and metabolic disorders ll KARO BIO AB (SE) 2004-11-04 US claimed
EP-1387825-A1 THYROID HORMONE RECEPTOR ANTAGONISTS FOR CARDIAC & METABOLIC DISORDERS II KARO BIO AB (SE) 2004-02-11 EP claimed
WO-2002092550-A1 THYROID HORMONE RECEPTOR ANTAGONISTS FOR CARDIAC AND METABOLIC DISORDERS II KARO BIO AB (SE) 2002-11-21 WO claimed
US-7319096-B2 Thyroid hormone receptor antagonists for cardiac and metabolic disorders II KARO BIO AB (SE) 2008-01-15 US disclosed
US-20040220147-A1 Thyroid hormone receptor antagonists for cardiac and metabolic disorders ll KARO BIO AB (SE) 2004-11-04 US disclosed
EP-1387825-A1 THYROID HORMONE RECEPTOR ANTAGONISTS FOR CARDIAC & METABOLIC DISORDERS II KARO BIO AB (SE) 2004-02-11 EP disclosed
WO-2002092550-A1 THYROID HORMONE RECEPTOR ANTAGONISTS FOR CARDIAC AND METABOLIC DISORDERS II KARO BIO AB (SE) 2002-11-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040220147-A1 Thyroid hormone receptor antagonists for cardiac and metabolic disorders ll TSHR, TRHR, THRA SLC1A5 1125/4885PDCD1 3128/4885CD274 2029/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.